Skip to main content
Clinical Trials/NCT00660062
NCT00660062
Terminated
Phase 4

Relapse Prevention in Patients With a Major Depressive Episode Treated With Electroconvulsive Treatment Using a Fixed Dose Range of Escitalopram Compared to a Fixed Dose of Nortriptyline (DUAG-7) A Randomised Controlled 6 Month Double-blind Study

Hillerod Hospital, Denmark1 site in 1 country47 target enrollmentAugust 2009

Overview

Phase
Phase 4
Intervention
escitalopram
Conditions
Major Depression
Sponsor
Hillerod Hospital, Denmark
Enrollment
47
Locations
1
Primary Endpoint
Hamilton depression rating scale
Status
Terminated
Last Updated
11 years ago

Overview

Brief Summary

The main purpose of this study is to investigate the relapse preventing efficacy of escitalopram in a dose range and nortriptylin in a single dose in patients having been treated successfully with a course of electroconvulsive treatment (ECT).

Detailed Description

This study records severity of depression and relapse in patients treated for a major depressive disorder with electroconvulsive treatment (ECT)in a period og 6 month after end of ECT treatment. Patients will be randomized into four groups treated with escitalopram 10 mg, 20 mg, 30 mg or nortriptylin 100 mg daily dosages. The primary outcome measure is relapse and secondary outcome measure is tolerability. The study is a multicenter trial within Denmark.

Registry
clinicaltrials.gov
Start Date
August 2009
End Date
November 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Hillerod Hospital, Denmark
Responsible Party
Principal Investigator
Principal Investigator

Klaus Martiny

Senior Consultant

Hillerod Hospital, Denmark

Eligibility Criteria

Inclusion Criteria

  • Remission from a major depressive episode after ECT treatment

Exclusion Criteria

  • Suicidality (Hamilton item 3 score of 3 or more)
  • Symptoms mania (MAS score of 15 or more)
  • Duration of actual depressive episode more than 2 years
  • Compulsory measures of any kind
  • Severe somatic illness
  • Pregnant or lactating subject
  • Known clinical relevant malabsorption.
  • Epilepsia
  • Clinically substantial cognitive deterioration due to ECT treatment
  • schizophrenia, schizopreniform or schizo-affective disorder

Arms & Interventions

Escitalopram 10 mg daily

Escitalopram 10 mg daily

Intervention: escitalopram

Escitalopram 20 mg daily

Escitalopram 20 mg daily

Intervention: escitalopram

escitalopram 30 mg daily

escitalopram 30 mg daily

Intervention: escitalopram

Nortriptylin 100 mg daily

Nortriptylin 100 mg daily

Intervention: nortriptyline

Outcomes

Primary Outcomes

Hamilton depression rating scale

Time Frame: 14 days

Secondary Outcomes

  • Drop out due to side-effects of drugs(14 days)

Study Sites (1)

Loading locations...

Similar Trials